A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao S.V., Kirsch B., Bhatt D.L., Budaj A., Coppolecchia R., Eikelboom J., James S.K., Jones W.S., Merkely B., Keller L. et al., 2022/10/18. Circulation, 146 (16) pp. 1196-1206. Peer-reviewed.
ici le détail